1. Home
  2. LNTH vs RGEN Comparison

LNTH vs RGEN Comparison

Compare LNTH & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantheus Holdings Inc.

LNTH

Lantheus Holdings Inc.

HOLD

Current Price

$66.73

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Logo Repligen Corporation

RGEN

Repligen Corporation

HOLD

Current Price

$165.56

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LNTH
RGEN
Founded
1956
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
8.2B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
LNTH
RGEN
Price
$66.73
$165.56
Analyst Decision
Strong Buy
Buy
Analyst Count
6
10
Target Price
$78.00
$174.90
AVG Volume (30 Days)
1.1M
618.1K
Earning Date
11-06-2025
10-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.39
0.03
Revenue
$1,525,933,000.00
$707,890,000.00
Revenue This Year
$0.01
$17.84
Revenue Next Year
$0.52
$12.44
P/E Ratio
$27.88
$5,383.25
Revenue Growth
1.95
11.74
52 Week Low
$47.25
$102.97
52 Week High
$111.29
$182.52

Technical Indicators

Market Signals
Indicator
LNTH
RGEN
Relative Strength Index (RSI) 65.42 57.69
Support Level $64.13 $156.01
Resistance Level $68.84 $167.74
Average True Range (ATR) 1.91 4.27
MACD 0.10 0.04
Stochastic Oscillator 75.07 81.59

Price Performance

Historical Comparison
LNTH
RGEN

About LNTH Lantheus Holdings Inc.

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: